Please login to the form below
Mitsubishi Tanabe Pharma
This page shows the latest Mitsubishi Tanabe Pharma news and features for those working in and with pharma, biotech and healthcare.
GSK files anaemia drug daprodustat in Japan, its first market
class called vadadustat in late-stage clinical testing that is licensed to Mitsubishi Tanabe Pharma in some Asian markets including Japan. ... Astellas Pharma meanwhile has rights to roxadustat in Japan and Europe and has phase 3 trials on the go in
Latest news
-
Voice biomarker device could diagnose depression, heart disease
The financing round was led by M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, Germany), with MP Healthcare Venture Management (the corporate venture capital arm of Mitsubishi Tanabe ... Pharma), Neoteny 4, LP, Canepa Healthcare,
-
Biogen picks up another drug from wide-ranging Ionis alliance
It was joined last year by Mitsubishi Tanabe Pharma’s Radicava/Radicut (edaravone) last year, which provides another options, but there is still a desperate need for additional therapies. ... Pharma’s ODM-109 (oral levosimendan) which was advanced to
-
Mitsubishi buys Israel's NeuroDerm for $1.1bn
Japan's Mitsubishi Tanabe Pharma has boosted its pipeline with a $1.1bn deal to buy NeuroDerm, an Israeli developer of central nervous system therapies. ... Adding ND0612 into the portfolio will help Mitsubishi meet its target of driving US sales to 80bn
-
FDA clears new ALS drug Radicava ahead of schedule
MT Pharma’s medicine will soon offer US patients an alternative to Sanofi’s Rilutek. ... Patients with the chronic neurodegenerative disease amyotrophic lateral sclerosis (ALS) have a new treatment option in the US after the FDA approved Mitsubishi
-
GSK starts late-stage trials of daprodustat
Also in phase III is Akebia Pharma's vadadustat, which has been licensed to Mitsubishi Tanabe Pharma in some Asian markets including Japan.
More from news
Approximately 1 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
4. Vadadustat is an inhibitor of hypoxiainducible factor (HIF)-prolyl hydroxylase (HIF-PH) from Akebia Therapeutics/ Mitsubishi Tanabe Pharma/Otsuka that targets anaemia in chronic kidney disease (CKD).
-
Deal Watch September 2016
India's Sun Pharmaceutical has partnered with Mitsubishi Tanabe Pharma to distribute and market 14 prescription drugs in Japan that Sun recently acquired from Novartis. ... Upfront $80m plus $830m in milestones [ex S. Korea]. 910. Raptor / Horizon Pharma.
-
Deal Watch October 2015
This was exemplified by the major asset swapping amongst pharma companies of last year. ... Collaboration, option to license. 339. Regeneron Pharmaceuticals/ Mitsubishi Tanabe Pharma. Fasinumab (REGN475), nerve growth factor mAb for musculoskeletal pain
-
Pharma deals during December 2014
OTX015 was originally in-licensed from Mitsubishi Tanabe Pharma Corporation in March 2012 following completion of phase I studies in healthy volunteers. ... See a table listing all the major pharma mergers, acquisitions and collaborations agreed during
-
Deal Watch table for July 2013
For an indepth analysis of these deals, read'Pharma deals during July 2013'. ... 210. Medicago / Mitsubishi Tanabe Pharma. Acquisition of 60% stake. Portfolio of flu and other vaccines based on VLPs (p2).
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Empowering Strategic Performance Ltd
OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
